What is the appropriate management for a 45-year-old female patient with nephrocalcinosis, recurrent kidney stones, hyperparathyroidism, and a history of kidney stone surgery, who also has a family history of kidney disease?

Case Report: Nephrocalcinosis in a 45-Year-Old Female with Hyperparathyroidism and Recurrent Kidney Stones

Clinical Presentation

This patient requires parathyroidectomy as the definitive treatment, as the presence of nephrocalcinosis and kidney stones in the setting of primary hyperparathyroidism constitutes symptomatic disease and is an absolute indication for surgical intervention. 1, 2

The combination of nephrocalcinosis, recurrent kidney stones, and hyperparathyroidism represents a classic presentation of symptomatic primary hyperparathyroidism (PHPT), where hypercalciuria drives calcium precipitation in both the renal parenchyma and collecting system 3, 4. The family history of kidney disease raises additional concern for hereditary stone-forming conditions that may coexist with or mimic PHPT 5.

Initial Diagnostic Workup

Confirm Primary Hyperparathyroidism

• Measure serum intact parathyroid hormone (iPTH) immediately, as primary hyperparathyroidism should be suspected when serum calcium is high or high-normal 1
• Obtain serum calcium, phosphorus, creatinine, and electrolytes to establish the biochemical diagnosis 1, 5
• Calculate estimated glomerular filtration rate (eGFR), as values <60 mL/min/1.73m² represent an independent indication for parathyroidectomy even without stones 1

Quantify Stone Burden and Nephrocalcinosis

• Perform unenhanced helical computed tomography (CT) to quantify stone burden and assess the extent of nephrocalcinosis, as this is the gold standard imaging modality 1, 3
• Renal ultrasound alone is insufficient, as CT provides superior detection of medullary nephrocalcinosis and small calcifications 5, 6
• Obtain stone analysis if any stone material is available, as composition (calcium phosphate, calcium oxalate, struvite, uric acid, or cystine) directs specific preventive measures 1, 7

Metabolic Stone Evaluation

• Collect one or two 24-hour urine specimens analyzing for volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine 1, 8, 7
• Measure urinary calcium-creatinine ratio to document hypercalciuria, which is present in the majority of PHPT patients with nephrocalcinosis 5, 9
• Assess for coexisting metabolic abnormalities such as hypocitraturia or hyperoxaluria that may persist after parathyroidectomy 3

Exclude Alternative Diagnoses

• Rule out distal renal tubular acidosis by checking serum bicarbonate and urine pH, as this condition also causes nephrocalcinosis with calcium phosphate stones 6
• Consider Bartter syndrome if there is hypokalemic metabolic alkalosis, polyuria, or a history of prematurity, as nephrocalcinosis is characteristic of types 1 and 2 5
• Evaluate for primary hyperoxaluria if urinary oxalate exceeds 75 mg/day without intestinal dysfunction, as this requires genetic testing and specialized management 10

Surgical Management

Parathyroidectomy Indications

Parathyroidectomy is mandatory in this patient because the presence of kidney stones or nephrocalcinosis categorizes PHPT as symptomatic disease, regardless of calcium levels or other parameters. 1, 2, 3

• Preoperative localization should include neck ultrasound and sestamibi (⁹⁹mTc-MIBI) scan to identify adenoma location 9
• Approximately 78% of PHPT patients with stones have solitary parathyroid adenomas, 9% have multiple adenomas, and 13% have multiglandular hyperplasia 9
• Intraoperative iPTH monitoring should be used to confirm adequate resection, with expected >50% decline from baseline 9

Expected Biochemical Changes Post-Surgery

• Serum calcium normalizes within 7 days, typically dropping from 3.3 mmol/L preoperatively to 2.1 mmol/L postoperatively 9
• Serum phosphorus increases from 0.7 mmol/L to 1.2 mmol/L within one week 9
• iPTH decreases dramatically from 28.8 pmol/L to 3.6 pmol/L 9
• 24-hour urinary calcium decreases by approximately 50%, from 7.2 mmol/day to 3.6 mmol/day 9

Concurrent Stone Management

• If obstructive stones are present, percutaneous nephrolithotomy (PCNL) or other stone removal procedures should be performed concurrently with parathyroidectomy 9
• Patients with hydroxyapatite stones have the highest prevalence of nephrocalcinosis (71%), followed by brushite stones (58%), compared to calcium oxalate stones (18%) 6
• Nephrocalcinosis extent positively correlates with urinary calcium excretion (287 mg/day vs 224 mg/day in those without nephrocalcinosis) 6

Medical Management Pending Surgery

Hydration Protocol

• Prescribe fluid intake sufficient to produce at least 2.5 liters of urine daily, which is the most powerful preventive measure against stone formation 8, 7, 11
• Recommend water, coffee, tea, and orange juice while strictly avoiding sugar-sweetened beverages, particularly phosphoric acid-acidified colas 7

Dietary Modifications

• Maintain normal dietary calcium intake of 1,000-1,200 mg daily from food sources—never restrict dietary calcium, as this paradoxically increases stone risk by increasing intestinal oxalate absorption 12, 8, 11
• Limit sodium intake to 2,300 mg (100 mEq) daily to reduce urinary calcium excretion 12, 8, 11
• Reduce animal protein to 5-7 servings of meat, fish, or poultry per week, as excess animal protein increases urinary calcium and reduces citrate 7, 11

Pharmacologic Therapy Considerations

• Thiazide diuretics should NOT be initiated preoperatively in PHPT patients, as they may worsen hypercalcemia 1
• Potassium citrate may be considered if severe hypocitraturia is present, but surgery remains the definitive treatment 8, 11
• Cinacalcet is FDA-approved for hypercalcemia in PHPT patients who cannot undergo parathyroidectomy, but this patient is a surgical candidate 13

Post-Parathyroidectomy Management

Stone Recurrence Risk

• Stone recurrence occurs in approximately 35% of patients within 2 years after parathyroidectomy, despite biochemical cure 9
• The risk of renal stone events remains elevated for at least 10 years after surgical cure compared to the general population 3, 4
• Early parathyroidectomy reduces stone recurrence rates to levels comparable to idiopathic stone disease 3

Ongoing Metabolic Monitoring

• Obtain 24-hour urine collection within 6 months of surgery to assess response and identify persistent metabolic abnormalities 8, 7
• Former PHPT patients may have persistently higher renal calcium excretion and lower serum phosphate compared to healthy controls, suggesting residual mineral disorder 3
• Annual renal ultrasound is recommended to monitor for new stone formation 10, 8

Long-Term Preventive Therapy

• Continue high fluid intake (≥2.5 L urine output daily) indefinitely 8, 7, 11
• If hypercalciuria persists post-operatively (>250 mg/day), thiazide diuretics should be offered at doses of hydrochlorothiazide 25 mg twice daily, chlorthalidone 25 mg once daily, or indapamide 2.5 mg once daily 8, 11
• If hypocitraturia persists (<320 mg/day), potassium citrate should be prescribed—use potassium citrate, NOT sodium citrate, as sodium increases urinary calcium excretion 8, 11
• Monitor serum potassium for hypokalemia with thiazides and hyperkalemia with potassium citrate 8, 7

Critical Pitfalls to Avoid

• Never delay parathyroidectomy in favor of medical stone management—surgery is curative for the underlying cause 1, 2, 3
• Never restrict dietary calcium preoperatively or postoperatively, as this increases oxalate absorption and stone risk 12, 11
• Never use calcium supplements instead of dietary calcium, as supplements increase stone risk by 20% 11
• Never assume stone risk normalizes after parathyroidectomy—lifelong preventive measures and monitoring are required 3, 4
• Never use sodium citrate instead of potassium citrate for alkalinization, as sodium worsens hypercalciuria 11

Prognosis and Follow-Up

• Nephrocalcinosis progression is largely reversible after successful parathyroidectomy, but residual risk persists 2
• Renal function should be monitored annually, as PHPT is associated with declining eGFR even after surgical cure 2
• Approximately 4% of patients experience parathyroid adenoma recurrence requiring reoperation 9
• Patients should be counseled that stone prevention requires lifelong adherence to hydration and dietary modifications even after biochemical cure 3, 4